Indeed, a bispecific anti-DLL4–anti-VEGF antibody notably improved the effects of paclitaxel on tumor growth inhibition and spontaneous lung and lymphatic node metastasis in a xenograft model of breast cancer, giving a good advantage over addition of anti-VEGF alone [236]. Here, DLL4 is linked to breast carcinoma.